Vetoquinol S.A. (0O1O.L) LSE
Currency In EUR
- General
- Statistics
- Historical Data
- Profile
- Financials
Vetoquinol S.A.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
2501
First IPO Date
March 05, 2013
Key Executives
| Name | Title | Pay | Year Born |
| Alain Masson | Deputy Chief Executive Officer & Pharmacist Manager | 206,074 | 1962 |
| Dominique Derveaux | Chief Operations Officer & Group Deputy Chief Executive Officer | 430,173 | 1969 |
| Matthieu Frechin | Chief Executive Officer & Non-Independent Chairman of the Board | 542,952 | 1969 |
| Philippe Gruet | Chief Scientific Officer | 0 | N/A |
| Xavier Berthet | Director of Group Communications | 0 | N/A |
| Laurent Thore | Director of Partnerships, Legal Affairs & Risks | 0 | N/A |
| Regis Vimal du Monteil | Chief Financial Officer | 0 | 1965 |
| Nathalie Arlecchini | Group Human Resources Director | 0 | N/A |
| Sandrine Perrier | Chief Information Officer | 0 | N/A |
Description
Vetoquinol S.A. is a pharmaceutical company dedicated to animal health, responsible for researching, formulating, and distributing veterinary medicines and other health-related products throughout Europe, the Americas, and the Asia Pacific. The firm offers a comprehensive range of solutions for various therapeutic areas, including pain and mobility management, inflammatory conditions, dermatology, hygiene, parasite control, udder health, infectious diseases, reproductive care, behavioral issues, internal medicine, and cardiovascular-renal disorders. These products are developed for a diverse clientele of animals, encompassing livestock such as cattle, sheep, pigs, and poultry, alongside domestic dogs. Founded in 1933, Vetoquinol S.A. maintains its headquarters in Lure, France, and operates as a subsidiary of Soparfin SCA.
